USE OF SOTROVIMAB
FOR COVID-19 IN ADULTS
DRUG GUIDELINE

Sotrovimab (Xevudy®) is provisionally registered for use in Australia for the treatment of COVID-19 in adults and adolescents (age ≥12 years and weighing at least 40 kg), who do not require oxygen and are at risk of disease progression to hospitalisation or death.1 The decision was made on the basis of short term efficacy and safety data. Sotrovimab appears to retain activity against Alpha; Beta; Gamma; Epsilon; Iota; and Delta variants of SARS-CoV-2.1

The National COVID-19 Clinical Evidence Taskforce (current as at 26/08/21) provides a conditional recommendation for use of sotrovimab as a neutralising antibody therapy for adults with COVID-19 who do not require initiation of oxygen and who have one or more risk factors for disease progression.3 (Certainty of evidence for outcomes: moderate for a composite endpoint of hospitalisation or death).3 This conditional recommendation is based on the results of the COMET-ICE trial, suggesting that there would be 46 fewer events (composite endpoint) per 1000 patients (CI 95% 52 fewer- 30 fewer).1,4 Currently use in pregnant or breastfeeding women or children and adolescents is NOT recommended outside randomised trials, which are currently underway.3 In addition, the Taskforce has made a consensus recommendation to address patients not included in the COMET-ICE trial, such as vaccinated and immunosuppressed patients.1,3 The Taskforce also recommended rigorous data collection on indications and key outcomes of patients who receive sotrovimab therapy.3

This guideline requires endorsement by your local Drug and Therapeutics Committee (DTC) prior to implementation.

Supply of sotrovimab for clinical trials takes precedence over supply for use outside of clinical trials. This guideline aims to provide supportive information for clinicians if they are considering prescribing sotrovimab when patients are not eligible for a clinical trial or when a clinical trial is not available.

This guideline should be used in conjunction with the sotrovimab resources available here:
- Individual Patient Use (IPU) Application Form (coming soon),
- Outcomes Reporting Form (coming soon),
- Patient Consent Form and further information regarding consent, and
- Patient Information Leaflet.

Drug Class1,2:
Recombinant human IgG1 monoclonal antibody targeting the spike protein of SARS-CoV-2, which is thought to prevent membrane fusion after the virus binds to the human ACE2 receptor.

Authorised Prescribers:
- Infectious disease physicians,
- Respiratory physicians,
- Other physicians in accordance with local governance regulations e.g. emergency physicians.
Indication for applying this guidance:\textsuperscript{1,3}:

In accordance with relevant DTC approval and the NSW Health Model of Care, sotrovimab may be considered for adult patients with a current diagnosis of COVID-19: • with symptom onset of no more than 5 days AND • who do not require oxygen AND • who are not vaccinated or only partially vaccinated unless the patient is immunosuppressed* AND • who have one or more of the following risk factors:
  o Diabetes (requiring medication)
  o Obesity (BMI >30 kg/m\textsuperscript{2})
  o Chronic kidney disease (i.e. eGFR <60 by Modification of Diet in Renal Disease (MDRD) formula)
  o Congestive heart failure (New York Heart Association (NYHA) class II or greater)
  o Chronic obstructive pulmonary disease (history of chronic bronchitis, chronic obstructive lung disease, or emphysema with dyspnoea on physical exertion)
  o Moderate-to-severe asthma (requiring an inhaled steroid to control symptoms or prescribed a course of oral steroids in the previous 12 months)
  o Age ≥55 years (or age >35 years if Aboriginal and/or Torres Strait Islander)

Clinical judgement should be used when assessing the severity of specific risk factors.

*For the purposes of this guidance, immunosuppressed patients are those that a) have a primary or acquired immunodeficiency such as haematological neoplasms, are post-transplant [solid organ (on immunosuppressive therapy) or haematopoietic stem cell transplant within 24 months], or have HIV/AIDS or other significant immunocompromising condition or b) are on/have been on recent immunosuppressive therapy such as chemotherapy, radiotherapy, high dose corticosteroids (equivalent to 20 mg or more of prednisone per day for 14 days or more) or are on biologic immunotherapies including most disease-modifying anti-rheumatic drugs (DMARDs).

Contraindications and Precautions:\textsuperscript{1-3,5}:

• **Hypersensitivity:** Contraindicated in patients with known hypersensitivity to sotrovimab, or any of the excipients (histidine, histidine hydrochloride monohydrate, sucrose, methionine, polysorbate 90) in the product, Chinese Hamster Ovary cell products or other recombinant human or humanised antibodies. Exercise caution in patients with a history of anaphylaxis to other medicines.

• **Pregnancy and breastfeeding:** Sotrovimab is pregnancy category B\textsuperscript{2}. There is potential for placental transfer of sotrovimab from the mother to the developing foetus. No information is available on the use of sotrovimab during breastfeeding. The amount present in breastmilk is likely to be very low as sotrovimab is a large protein molecule. Discontinuation of breastfeeding may be considered. For management of pregnant and breastfeeding women with COVID-19, see National COVID-19 Clinical Evidence Taskforce guidelines.

• **Paediatric population:** The safety and efficacy of sotrovimab has not been established in children <12 years of age or weighing <40 kg.

**Drug Interactions\textsuperscript{1}:**

No formal interaction studies have been conducted with sotrovimab. Sotrovimab is not renally excreted or metabolised by the CYP450 enzymes. (Sotrovimab is degraded by proteolytic enzymes widely distributed in the body and not restricted to hepatic tissue).

As at 26/8/21, drug interaction texts such as Liverpool COVID-19 Drug Interactions tool\textsuperscript{6} and Micromedex drug interaction tool\textsuperscript{7} (CIAP link) do not identify any drug interactions. Contact the local pharmacy department or medicines information service for further advice.

Interaction with COVID-19 vaccination has not been determined. The US Centers for Disease Control and Prevention advises delaying COVID-19 vaccination until 90 days after administration of monoclonal antibodies as part of COVID-19 treatment, to avoid potential interference with the immune response to the COVID-19 vaccination.\textsuperscript{8} This advice applies to those who have not received any vaccine dose as well as those who have received the first dose but not the second dose.\textsuperscript{8}
Presentation and Storage¹:
- Available as a single use vial of 500 mg in 8 mL (62.5 mg/mL) concentrated injection solution for infusion. The solution in the vial should be clear and colourless to yellow or brown.
- Store refrigerated at 2 - 8°C in original package. Protect from light. Do not freeze.

Dose¹,²:

The recommended dose is 500 mg as a single dose intravenous infusion over 30 minutes

No dose adjustments for renal or hepatic function or age are required.

Preparation and Administration¹,²:
- The occupational hazard of intermittent low dose exposure to sotrovimab is not known. Wear a mask and gloves when preparing the infusion solution to minimise exposure.
- It is recommended that the name and the batch number of the administered product is clearly recorded in order to improve traceability.
- Preferably use immediately after dilution. If this is not possible, the diluted solution may be stored at room temperature for up to 6 hours (include infusion time) or stored in the refrigerator for up to 24 hours (include infusion time).
- Personnel and equipment to manage anaphylaxis must be present during infusion and for at least 60 minutes post-infusion.
- Please note, the Australian Injectable Drugs Handbook (AIDH) monograph for sotrovimab is pending publication in early September.

<table>
<thead>
<tr>
<th>Preparation Steps</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Remove one vial containing 8 mL sotrovimab solution from refrigerator at least 15 minutes before preparation of the infusion.</td>
</tr>
<tr>
<td>2. Visually inspect vial to ensure no particulate matter is present or damage to the vial. (Discard if present).</td>
</tr>
<tr>
<td>3. Gently swirl the vial several times without creating air bubbles before using. (Do NOT shake vigorously).</td>
</tr>
<tr>
<td>4. Withdraw 8 mL from a 50 mL or 100 mL sodium chloride 0.9% infusion bag or glucose 5% infusion bag. If local protocols allow, this step may be omitted.</td>
</tr>
<tr>
<td>5. Withdraw 8 mL solution from the sotrovimab vial.</td>
</tr>
<tr>
<td>6. Inject 8 mL of sotrovimab solution into selected infusion bag.</td>
</tr>
<tr>
<td>7. Prior to infusion, to mix, gently rock the infusion bag back and forth 3 to 5 times. Do NOT invert the bag. Avoid forming air bubbles.</td>
</tr>
<tr>
<td>8. Discard the vial including any unused solution.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Administration Steps</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Do not use the same IV line to administer other medications at the same time.</td>
</tr>
<tr>
<td>2. Attach an infusion set to the infusion bag using standard bore tubing. Administer using a 0.2 micrometre in-line filter.</td>
</tr>
<tr>
<td>3. Prime the infusion set with sotrovimab infusion and then infuse intravenously over 30 minutes (until the bag is finished) via a central or peripheral line.</td>
</tr>
<tr>
<td>4. After the sotrovimab infusion is completed, flush the giving set with at least 20 mL of 0.9% sodium chloride/glucose 5% (at the same rate as the sotrovimab infusion).</td>
</tr>
<tr>
<td>5. <strong>Observe the patient during the infusion and for 60 minutes after infusion cessation</strong> in case of hypersensitivity reactions or anaphylaxis.</td>
</tr>
</tbody>
</table>
Monitoring Requirements\textsuperscript{1,4,5}:

Monitor the patient for adverse effects (see Adverse Effects section below).

Infusion reactions include fever, chills, dizziness, dyspnoea, pruritis and rash. For mild to moderate infusion reactions, slow or stop the infusion and treat accordingly (AIDH monograph draft), noting that in the COMET-ICE trial, mild hypersensitivity reactions did not require pausing or discontinuation of the infusion.\textsuperscript{4} Anaphylactic reactions are rare but are a medical emergency. Stop the infusion and commence treatment immediately.

Adverse Effects\textsuperscript{1,4}:

It may be difficult to distinguish between adverse effects of sotrovimab and signs and symptoms of COVID-19. As the proposed use is for a provisionally approved medicine which has no relevant post-marketing data, it is important to document and report all (from possible to confirmed) adverse effects experienced by the patient during treatment to inform its safety profile and future use. Refer to product information for complete list of possible adverse effects.

- **Common (>1%)**: Diarrhoea (1%), hypersensitivity reactions (includes rash (2%), infusion-related reaction, bronchospasm).
- **Rare**: Anaphylaxis.

Reporting:

Access via the IPU/Prescribing Declaration pathway will enable appropriate medicines governance and ensure the collection and analysis of patient outcomes and systematic monitoring of medicines use. The prescribing clinician is responsible for reporting medication errors and adverse events occurring as a result of sotrovimab treatment:

- Adverse events related to medicines should be reported to the TGA and via the hospital ims+ or Riskman system.
- Approval of sotrovimab IPU should be accompanied with reporting of clinical outcomes. Prescribing Declarations or IPU applications and outcome reporting should occur as per local governance processes. A NSW TAG-developed drug registry using an online application and outcome reporting processes for sotrovimab will be released soon. See \url{http://www.nswtag.org.au/resources-for-experimental-medicines-for-the-treatment-of-covid-19/}. Contact your local DTC or pharmacist for further information.

References:


Note: Australian Injectable Drugs Handbook (AIDH) monograph for sotrovimab to be reviewed and referenced when it is published in the near future.